Change in Renal Function and Its Impact on Survival in Chronic Kidney Disease Patients Bridged to Heart Transplantation With a Left Ventricular Assist Device.
Journal
ASAIO journal (American Society for Artificial Internal Organs : 1992)
ISSN: 1538-943X
Titre abrégé: ASAIO J
Pays: United States
ID NLM: 9204109
Informations de publication
Date de publication:
01 11 2021
01 11 2021
Historique:
pubmed:
27
3
2021
medline:
15
12
2021
entrez:
26
3
2021
Statut:
ppublish
Résumé
The study investigates the incidence of change in renal function and its impact on survival in renal dysfunction patients who were bridged to heart transplantation with a left ventricular assist device (BTT-LVAD). BTT-LVAD patients with greater than or equal to moderately reduced renal function (estimated glomerular filtration rate [eGFR] ≤ 60 ml/min/1.73 m2) at the time of listing between 2008 and 2018 were identified from a prospectively maintained database of the United Network for Organ Sharing. Patients with a baseline eGFR less than or equal to 15 ml/min/1.73 m2 or on dialysis were excluded. Patients were divided into three groups based on percent change ([Pretransplant eGFR - listing eGFR/listing glomerular filtration rate (GFR)] × 100) in eGFR: Improvement greater than or equal to 10%, no change, decline greater than or equal to 10%, and their operative outcomes were compared. Posttransplant survival was estimated and compared among the three groups with the Kaplan-Meier survival curves and the log-rank test. Cox proportional hazards modeling was used to identify predictors of posttransplant survival. Out of 14,395 LVAD patients, 1,622 (11%) met the inclusion criteria. At the time of transplant, 900 (55%) had reported an improvement in eGFR greater than or equal to 10%, 436 (27%) had no change, and 286 (18%) experienced a decline greater than or equal to 10%. Postoperatively, the incidence of dialysis was higher in the decline than in the unchanged or improved groups (22% vs. 12% vs. 12%; p = 0.002). After a median follow-up of 5 years, there was no difference in posttransplant survival among the stratified groups (improved eGFR: 24.8%, unchanged eGFR: 23.2%, declined eGFR: 20.3%; p = 0.680). On Cox proportional hazard modeling, independent predictors of worse survival were: [hazard ratio: 95% CI; p] history of diabetes (1.43 [1.13-1.81]; p = 0.002) or tobacco use (1.40 [1.11-1.79]; p = 0.005) and ischemic time greater than 4 hours (1.36 [1.03-1.76]; p = 0.027). More than half of the patients with compromised renal function who undergo BTT-LVAD demonstrate an improvement in renal function at the time of transplant. A 10% change in GFR while listed was not associated with worse posttransplant survival.
Identifiants
pubmed: 33769354
doi: 10.1097/MAT.0000000000001384
pii: 00002480-202111000-00004
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1204-1210Informations de copyright
Copyright © ASAIO 2021.
Déclaration de conflit d'intérêts
Disclosure: The authors have no conflicts of interest to report.
Références
Daimee UA, Wang M, Papernov A, et al.: Renal function changes following left ventricular assist device implantation. Am J Cardiol. 120: 2213–2220, 2017.
Kilic A, Chen CW, Gaffey AC, Wald JW, Acker MA, Atluri P: Preoperative renal dysfunction does not affect outcomes of left ventricular assist device implantation. J Thorac Cardiovasc Surg. 156: 1093–1101.e1, 2018.
Okoh AK, Kambiz K, Unnikrishnan D, et al.: Effect of transcatheter aortic valve implantation on renal function in patients with previous renal dysfunction. Am J Cardiol. 124: 85–89, 2019.
Butler J, Geisberg C, Howser R, et al.: Relationship between renal function and left ventricular assist device use. Ann Thorac Surg. 81: 1745–1751, 2006.
Genovese EA, Dew MA, Teuteberg JJ, et al.: Early adverse events as predictors of 1-year mortality during mechanical circulatory support. J Heart Lung Transplant. 29: 981–988, 2010.
Givens RC, Topkara VK: Renal risk stratification in left ventricular assist device therapy. Expert Rev Med Devices. 15: 27–33, 2018.
Iwashima Y, Yanase M, Horio T, et al.: Serial changes in renal function as a prognostic indicator in advanced heart failure patients with left ventricular assist system. Ann Thorac Surg. 93: 816–823, 2012.
Sandner SE, Zimpfer D, Zrunek P, et al.: Renal function and outcome after continuous flow left ventricular assist device implantation. Ann Thorac Surg. 87: 1072–1078, 2009.
Kirklin JK, Naftel DC, Kormos RL, et al.: Quantifying the effect of cardiorenal syndrome on mortality after left ventricular assist device implant. J Heart Lung Transplant. 32: 1205–1213, 2013.
Borgi J, Tsiouris A, Hodari A, Cogan CM, Paone G, Morgan JA: Significance of postoperative acute renal failure after continuous-flow left ventricular assist device implantation. Ann Thorac Surg. 95: 163–169, 2013.
Mohamedali B, Bhat G: The influence of pre-left ventricular assist device (LVAD) implantation glomerular filtration rate on long-term LVAD outcomes. Heart Lung Circ. 26: 1216–1223, 2017.
Sandner SE, Zimpfer D, Zrunek P, et al.: Renal function after implantation of continuous versus pulsatile flow left ventricular assist devices. J Heart Lung Transplant. 27: 469–473, 2008.
Holman WL, Naftel DC, Eckert CE, Kormos RL, Goldstein DJ, Kirklin JK. Durability of left ventricular assist devices: Interagency registry for mechanically assisted circulatory support (INTERMACS) 2006 to 2011. J Thorac Cardiovasc Surg. 146:437–441 e431, 2013.
Singh M, Shullo M, Kormos RL, et al.: Impact of renal function before mechanical circulatory support on posttransplant renal outcomes. Ann Thorac Surg. 91: 1348–1354, 2011.
Haglund NA, Feurer ID, Dwyer JP, et al.: Does renal dysfunction and method of bridging support influence heart transplant graft survival? Ann Thorac Surg. 98: 835–841, 2014.
Al Aly Z, Abbas S, Moore E, Diallo O, Hauptman PJ, Bastani B: The natural history of renal function following orthotopic heart transplant. Clin Transplant. 19: 683–689, 2005.
González-Vílchez F, Arizón JM, Segovia J, et al.; ICEBERG Study Group: Chronic renal dysfunction in maintenance heart transplant patients: The ICEBERG study. Transplant Proc. 46: 14–20, 2014.
Reese PP, Shults J, Bloom RD, et al.: Functional status, time to transplantation, and survival benefit of kidney transplantation among wait-listed candidates. Am J Kidney Dis. 66: 837–845, 2015.
Goldstein BA, Thomas L, Zaroff JG, Nguyen J, Menza R, Khush KK: Assessment of heart transplant waitlist time and pre- and post-transplant failure: A mixed methods approach. Epidemiology. 27: 469–476, 2016.
Meier-Kriesche HU, Port FK, Ojo AO, et al.: Effect of waiting time on renal transplant outcome. Kidney Int. 58: 1311–1317, 2000.
Gammie JS, Edwards LB, Griffith BP, Pierson RN 3rd, Tsao L: Optimal timing of cardiac transplantation after ventricular assist device implantation. J Thorac Cardiovasc Surg. 127: 1789–1799, 2004.
Kao W, Winkel E, Costanzo MR: Candidate evaluation and selection for heart transplantation. Curr Opin Cardiol. 10: 159–168, 1995.
Russo MJ, Chen JM, Sorabella RA, et al.: The effect of ischemic time on survival after heart transplantation varies by donor age: an analysis of the United Network for Organ Sharing database. J Thorac Cardiovasc Surg. 133: 554–559, 2007.
Delgado DH, Miriuka SG, Cusimano RJ, Feindel C, Rao V, Ross HJ: Use of basiliximab and cyclosporine in heart transplant patients with pre-operative renal dysfunction. J Heart Lung Transplant. 24: 166–169, 2005.
Angermann CE, Störk S, Costard-Jäckle A, et al.: Reduction of cyclosporine after introduction of mycophenolate mofetil improves chronic renal dysfunction in heart transplant recipients–the IMPROVED multi-centre study. Eur Heart J. 25: 1626–1634, 2004.